Education
About Us
Working with TipRanks
Follow Us
Alliance Pharma PLC (GB:APH)
LSE:APH
APH Stock Chart & Stats
Day’s Range― - ―
52-Week Range24.55p - 66.20p
Previous CloseN/A
Volume68.57K
Average Volume (3M)3.98M
Market Cap
£347.04M
Enterprise Value310.64M
Total Cash (Recent Filing)£22.44M
Total Debt (Recent Filing)£113.65M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Sep 30, 2025EPS Estimate
2.5Last Dividend Ex-Date
Jun 22, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding540,565,550
10 Day Avg. Volume1,991,481
30 Day Avg. Volume3,979,157
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.89
Price to Cash Flow (P/CF)12.10
P/FCF Ratio9.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
63.25pPrice Target Upside-1.48% Downside
Rating ConsensusHold
Number of Analyst Covering3
---
Alliance Pharma News
PremiumCompany Announcements
Alliance Pharma Releases 2024 Annual Report
PremiumCompany Announcements
Alliance Pharma Reports Steady 2024 Results and Announces Acquisition
PremiumCompany Announcements
Alliance Pharma Announces Change in Major Holdings
PremiumCompany Announcements
Alliance Pharma Shareholders Approve Acquisition by Aegros Bidco
PremiumCompany Announcements
Alliance Pharma Receives Final Increased Cash Offer from Aegros Bidco
PremiumCompany Announcements
Alliance Pharma Sees Major Stake Acquisition by Sand Grove CapitalPremiumCompany Announcements
Alliance Pharma Adjourns Meetings for Acquisition Discussions---
Bulls Say, Bears Say
Bulls Say
AcquisitionDBAY's initial offer was raised by 20% to 62.5p, and the acquisition of Alliance is expected to complete.
Debt ManagementNet debt (£83.2m at 30 June) and leverage (1.81x at 30 June) were both a nudge better, and are expected to fall further in H2, with the company targeting c.1.5x.
Bears Say
Product PerformanceKey consumer products like Nizoral and Amberen continue to struggle and were below expectations.
Revenue DeclineRevenues declined 1% to £180.3m, which is below consensus expectations.
Supply Chain IssuesRestructuring of the China supply chain for key product Kelo-Cote is taking longer than expected.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.40%
Mutual Funds
― Other Institutional Investors
99.46% Public Companies and
Individual Investors
APH FAQ
What was Alliance Pharma PLC’s price range in the past 12 months?
Alliance Pharma PLC lowest share price was 24.55p and its highest was 66.20p in the past 12 months.
What is Alliance Pharma PLC’s market cap?
Alliance Pharma PLC’s market cap is £347.04M.
When is Alliance Pharma PLC’s upcoming earnings report date?
Alliance Pharma PLC’s upcoming earnings report date is Sep 30, 2025 which is in 166 days.
How were Alliance Pharma PLC’s earnings last quarter?
Alliance Pharma PLC released its earnings results on Apr 08, 2025. The company reported -0.028p earnings per share for the quarter, missing the consensus estimate of 0.025p by -0.053p.
Is Alliance Pharma PLC overvalued?
According to Wall Street analysts Alliance Pharma PLC’s price is currently Overvalued.
Does Alliance Pharma PLC pay dividends?
Alliance Pharma PLC pays a Annually dividend of 1.183p which represents an annual dividend yield of N/A. See more information on Alliance Pharma PLC dividends here
What is Alliance Pharma PLC’s EPS estimate?
Alliance Pharma PLC’s EPS estimate is 2.5.
How many shares outstanding does Alliance Pharma PLC have?
Alliance Pharma PLC has 540,565,550 shares outstanding.
What happened to Alliance Pharma PLC’s price movement after its last earnings report?
Alliance Pharma PLC reported an EPS of -0.028p in its last earnings report, missing expectations of 0.025p. Following the earnings report the stock price went up 0.156%.
Which hedge fund is a major shareholder of Alliance Pharma PLC?
Currently, no hedge funds are holding shares in GB:APH
---
Alliance Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
63.25p (-1.48% Downside)
63.25p (-1.48% Downside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
72.34%
12-Months-Change
Fundamentals
Return on Equity
-5.04%
Trailing 12-Months
Asset Growth
-11.03%
Trailing 12-Months
Company Description
Alliance Pharma PLC
Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. It holds the marketing rights of approximately 80 consumer healthcare and prescription medicine products. The company also offers medical devices, food supplements, and cosmetics. Alliance Pharma plc provides its products under the Aloclair, Anbesol, Asthon and Parsons, Atopiclair, Forceval, Hydromol, Kelo-cote, Macushield, Vamousse, Nizoral, and Amberen brand names. The company was founded in 1996 and is headquartered in Chippenham, the United Kingdom.
---
APH Stock 12 Month Forecast
Average Price Target
63.25p
▼(-1.48% Downside)
Technical Analysis
Best Analysts Covering APH
1 Year
1 Year Success Rate
1/1 ratings generated profit
1 Year Average Return
+58.50%
reiterated a buy rating 10 months ago
Copying Paul Cuddon's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +58.50% per trade.
---